Company profile: Izotropic
1.1 - Company Overview
Company description
- Provider of breast CT imaging solutions, offering a high-resolution, 3D Breast CT Imaging System that captures approximately 500 images in a 10-second scan without compression; a robotic-guided Breast CT Biopsy System for imaging and sampling suspicious lesions and tumors for pathology testing; and Breast CT–based breast density measurement using 3D images and algorithms to estimate glandular volumes.
Products and services
- Breast Density Measurement using Breast CT: An algorithm-based method that quantifies glandular tissue volumes from 3D breast images, delivering accurate breast density assessment using the Breast CT Imaging System
- Izotropic Breast CT Biopsy System: A robotic-guided biopsy platform that images and samples suspicious breast lesions and tumors using 3D CT guidance, enabling precise tissue acquisition for pathology testing
- Izotropic Breast CT Imaging System: A compression-free design that produces high-resolution, 3D breast images by capturing approximately 500 frames during a single 10-second scan for detailed lesion visualization
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Izotropic
Pierian Biosciences
HQ: United States
Website
- Description: Provider of cancer diagnostics, including ChemoINTEL, a chemosensitivity assay that measures tumor cell apoptotic response to cytotoxic agents to aid chemotherapy selection; ImmunoINTEL, a flow cytometry-based platform that characterizes and quantifies immune and tumor cell populations for immunotherapy selection; and PathwayINTEL, a proteomic profiling assay that identifies oncogenic drivers to help select targeted or biologic therapies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Pierian Biosciences company profile →
Arius Research
HQ: Canada
Website
- Description: Provider of biotechnology solutions centered on the discovery and development of antibody therapeutics, primarily targeting breast, prostate, ovarian, colorectal, pancreatic and lung cancers, leukemia, and melanoma, leveraging its FunctionFIRST platform to identify monoclonal antibodies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Arius Research company profile →
Allarity
HQ: United States
Website
- Description: Provider of biopharmaceutical oncology therapies and predictive diagnostics for personalized cancer treatment, utilizing DRP Technology to predict patient response and refine patient selection. Pipeline includes Dovitinib for renal cell carcinoma, Stenoparib, LiPlaCis, and 2X-111.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Allarity company profile →
NovelStem
HQ: United States
Website
- Description: Provider of diagnostic technology and biotech solutions, including NewStem Diagnostic for early detection of anti-cancer drug resistance aiding targeted cancer treatments, NewStem Therapeutics using proprietary HhESCs for drug and gene screenings to identify genes and drugs for genetic and epigenetic disorders, NewStem Cell Growth Media to improve hPSC growth, and Net Force, a publishing franchise on digital crime, espionage, and crypto.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full NovelStem company profile →
WntResearch
HQ: Sweden
Website
- Description: Provider of anti-metastatic cancer therapies targeting WNT5A signaling. Pipeline includes Foxy-5, a peptide drug candidate that mimics WNT5A to reduce cancer cell mobility and spread (Phase I; reconstitutes Wnt-5a effects in breast cancer cells), and Box-5, a peptide in preclinical development that antagonizes Wnt-5a.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full WntResearch company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Izotropic
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Izotropic
2.2 - Growth funds investing in similar companies to Izotropic
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Izotropic
4.2 - Public trading comparable groups for Izotropic
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →